Last reviewed · How we verify
Candida Skin Test Antigen
Candida skin test antigen is an intradermal diagnostic agent that elicits a delayed-type hypersensitivity reaction to assess cell-mediated immune function.
Candida skin test antigen is an intradermal diagnostic agent that elicits a delayed-type hypersensitivity reaction to assess cell-mediated immune function. Used for Assessment of cell-mediated immune function in immunocompromised patients, Evaluation of delayed-type hypersensitivity response.
At a glance
| Generic name | Candida Skin Test Antigen |
|---|---|
| Also known as | Candin(R), Manufactured by Allermed Laboratories of USA. |
| Sponsor | Aeras |
| Drug class | Diagnostic antigen / Immunological test |
| Modality | Biologic |
| Therapeutic area | Immunology / Diagnostics |
| Phase | FDA-approved |
Mechanism of action
The antigen is injected intradermally and triggers a Type IV hypersensitivity response in individuals with prior Candida exposure and intact T-cell immunity. The resulting induration at the injection site is measured to evaluate immune competence, particularly in immunocompromised patients or those with suspected immunodeficiency. A positive reaction indicates preserved cell-mediated immunity, while anergy (lack of response) may suggest severe immunosuppression.
Approved indications
- Assessment of cell-mediated immune function in immunocompromised patients
- Evaluation of delayed-type hypersensitivity response
Common side effects
- Local induration and erythema at injection site
- Systemic hypersensitivity reactions
Key clinical trials
- Candin for the Treatment of Common Warts (PHASE3)
- Comparison Between Intralesional Injection of Plasma Rich Platelets and Candida Antigen in Plane Warts (PHASE4)
- Candin Safety & Efficacy Study for the Treatment of Warts (PHASE2)
- Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris) (PHASE2)
- A Study of MVA85A in Healthy Infants (PHASE2)
- Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in HIV-Infected Adults (C-030-485) (PHASE2)
- Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Candida Skin Test Antigen CI brief — competitive landscape report
- Candida Skin Test Antigen updates RSS · CI watch RSS
- Aeras portfolio CI